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Antigen-based therapies (ABTs) fail to restore normo-
glycemia in newly diabetic NOD mice, perhaps because
too few b-cells remain by the time that ABT-induced
regulatory responses arise and spread. We hypothe-
sized that combining a fast-acting anti-inflammatory
agent with an ABT could limit pathogenic responses
while ABT-induced regulatory responses arose and
spread. g-Aminobutyric acid (GABA) administration can
inhibit inflammation, enhance regulatory T-cell (Treg)
responses, and promote b-cell replication in mice. We
examined the effect of combining a prototypic ABT,
proinsulin/alum, with GABA treatment in newly diabetic
NOD mice. Proinsulin/alum monotherapy failed to cor-
rect hyperglycemia, while GABA monotherapy restored
normoglycemia for a short period. Combined treatment
restored normoglycemia in the long term with apparent
permanent remission in some mice. Proinsulin/alum
monotherapy induced interleukin (IL)-4– and IL-10–
secreting T-cell responses that spread to other b-cell
autoantigens. GABA monotherapy induced moderate
IL-10 (but not IL-4) responses to b-cell autoantigens.
Combined treatment synergistically reduced spontane-
ous type 1 T-helper cell responses to autoantigens,
ABT-induced IL-4 and humoral responses, and insulitis,
but enhanced IL-10 and Treg responses and promoted
b-cell replication in the islets. Thus, combining ABT with
GABA can inhibit pathogenic T-cell responses, induce
Treg responses, promote b-cell replication, and effec-
tively restore normoglycemia in newly diabetic NOD
mice. Since these treatments appear safe for humans,
they hold promise for type 1 diabetes intervention.
The Immune Tolerance Network and Juvenile Diabetes
Research Foundation Joint Taskforce as well as recent
commentaries, have opined that ideal immunotherapies
for type 1 diabetes (T1D) should reduce proinflammatory
autoimmune responses, promote regulatory responses,
and enhance b-cell survival and replication (1–4). Theo-
retically, antigen-based therapies (ABTs) are appealing
because ABTs can induce antigen-specific regulatory
responses with little interference with systemic immu-
nity. Previous studies (5,6) have shown that ABT can in-
duce strong regulatory T-cell (Treg) responses after T1D
onset and prolong the survival of syngeneic islet grafts in
preconditioned diabetic NOD mice. However, ABTs have
little or no ability to restore normoglycemia in newly di-
abetic NOD mice. The inability of ABT to protect residual
b-cell mass in newly diabetic NOD mice may stem from
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the 10–14 days that it takes for ABT to induce maximal
immune responses to the administered autoantigen and
the time it takes for Treg responses to spread to other
b-cell autoantigens (reviewed in 4). Consequently, by the
time ABT-induced regulatory responses peak in newly
diabetic NOD mice, insufficient b-cell mass remains and
the treatments appear ineffective. We hypothesized
that administering a fast-acting anti-inflammatory agent
along with an ABT could limit pathogenic autoimmune
responses while ABT-induced regulatory responses arise
and spread, and that their combined effects could syner-
gistically inhibit inflammation and promote restoration of
normoglycemia.
T cells express g-aminobutyric acid (GABA) receptors
(GABA-Rs) (7–9). The activation of GABA-Rs can inhibit
autoreactive type 1 T-helper (Th1) cell responses and
antigen-presenting cell function directly ex vivo (7,10–15),
but increase the number of Tregs in vivo (13,16). GABA-R
activation inhibits inflammation and disease in mouse
models of T1D (10,13,17), rheumatoid arthritis (11), mul-
tiple sclerosis (12), and type 2 diabetes (16). Notably,
GABA administration also very effectively restored nor-
moglycemia in wild-type mice that had been rendered di-
abetic by multiple low doses of streptozocin, which
induces low-grade b-cell autoimmunity (13). However,
when the same treatment was given to mildly hypergly-
cemic NOD mice (which have a more robust autoimmune
response), 60% of the mice did not respond to treatment
and 40% of the mice displayed a delayed disease progres-
sion for ,6 weeks (13). Thus, GABA monotherapy has
limited beneficial effects in newly diabetic NOD mice.
Because of its rapid anti-inflammatory effects, GABA is
an excellent candidate for therapeutic testing in combina-
tion with ABTs. Importantly, GABA also promotes mouse
and human b-cell survival and replication (13,15,18,19).
Long-term treatment with GABA neither induces leu-
kopenia (10) nor desensitizes immune cells to GABA
(10,11), and GABA appears to be safe for human con-
sumption (20–22).
The aim of this study was to investigate the thera-
peutic potential of ABT in combination with GABA. As
a prototypic ABT, we chose to study proinsulin, because
it is a key b-cell autoantigen and contains more T-cell
determinants than insulin or fragments thereof. We
assessed the ability of each monotherapy and their
combination to restore euglycemia in newly diabetic
NOD mice, their impact on autoimmune and immuno-
regulatory responses, and their ability to promote b-cell
replication.
RESEARCH DESIGN AND METHODS
Mice
NOD mice (Taconic Farms, Derwood, MD) were housed in
a specific pathogen-free facility. Only female NOD mice
were used. All experimental procedures were approved by
the Chancellor’s Animal Research Committee at the Uni-
versity of California, Los Angeles.
Treatment
We monitored the blood glucose levels of female NOD
mice, and those with two blood glucose levels .250
mg/dL on consecutive days were considered to be newly
diabetic. The mice were randomly assigned to groups
that continually received water containing 0, 2, 6, or
20 mg/mL GABA, pH 7.2 (Sigma-Aldrich, St. Louis,
MO). Each mouse consumed about 5 mL of water per day.
Some newly diabetic mice also received 100 mg of pro-
insulin (provided by Eli Lilly, Indianapolis, IN) complexed
with alum (Pierce, Rockford, IL) intraperitoneally. The
mice were boosted with the same dose of proinsulin/
alum 10 days after the first vaccination. The mice were
monitored for the recurrence of hyperglycemia.
ELISPOT Assay
NOD mice at 15 weeks of age received proinsulin/alum,
GABA (20 mg/mL), or combined therapy, as described
above. Control groups included untreated and alum
(alone)–injected mice. Ten days after the second vac-
cination, the frequency of antigen-specific interferon-g
(IFN-g)–, interleukin (IL)-4–, and IL-10–secreting splenic
T cells in the different groups of mice was determined by
ELISPOT assays, as previously described (23), with the
addition of using JES5–16E3 and JES5–2A5 (BioLegend,
San Diego, CA) as capture and detection antibodies for
IL-10. The tested antigens included control self-antigen
mouse serum albumin (MSA), and b-cell autoantigens
GAD65 (Diamyd Medical), HSPp277, and proinsulin (all
at 100 mg/mL). The cells in medium alone were used as
the negative controls, while cells challenged with 1 mg/mL
anti-CD3 provided positive controls.
Flow Cytometry Analysis of Tregs
The percentages of splenic CD4+Foxp3+ Tregs in individ-
ual mice were determined by flow cytometry, as per our
previous study (16).
ELISA for Proinsulin Autoantibodies
The concentrations of serum anti-proinsulin IgG, IgG1,
and IgG2a in individual mice were determined by ELISA
(5) using proinsulin as the antigen.
Histological Examination
Insulitis scores were determined from at least 20 islets
per pancreas of individual diabetic mice 10 days after
initiating treatment, as previously described (24).
Analysis of b-Cell Replication
b-Cell replication and insulin+ cells in mouse islets were
assessed 10 days after initiating treatment as previously
described (19).
Statistical Analysis
Data are expressed as the mean 6 SEM. The difference
between groups was analyzed by Student t test, and the
periods of normoglycemia between groups were analyzed
by the log-rank test. A P value of ,0.05 was considered
statistically significant.
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RESULTS
GABA Monotherapy Dosing Studies
After NOD mice develop hyperglycemia (2 consecutive
days of blood glucose levels .250 mg/dL), they generally
progress to severe hyperglycemia within 1 week (Fig. 1A).
We found that oral treatment with GABA at 2 mg/mL,
a dose can inhibit the development and severity of rheu-
matoid arthritis in mice (11) as well as the development
of insulin resistance in a high-fat diet mouse model (16),
failed to correct hyperglycemia in newly diabetic mice
(data not shown), suggesting that T1D intervention will
require a higher dosage. Treatment with GABA at 6 mg/mL
delayed disease progression for a very short period (Fig.
1B). Treatment with GABA at 20 mg/mL restored normo-
glycemia in all mice (Fig. 1C). Eight of 10 mice maintained
euglycemia for 2–5 weeks, and two mice did so for 18–23
weeks (Fig. 1C). Thus, oral GABA monotherapy at an ap-
propriate dose can quickly correct hyperglycemia and main-
tain normoglycemia for a short period in newly diabetic
mice, extending previous findings (13). These observations
underscore the need for systematic studies to identify an
effective GABA dose and frequency of administration to
inhibit inflammatory responses in humans. The therapeu-
tic effects of GABA may be mediated by the ability of GABA
to inhibit autoreactive Th1 responses (7,10,11), enhance
Treg responses (13,16), and promote the functional recov-
ery and replication of b-cells (13,18,19).
Combined Therapy Provides Synergistic Therapeutic
Effects
Next, we tested whether combined therapies of proinsulin/
alum vaccination with GABA (20 mg/mL) could correct
hyperglycemia and better maintain normoglycemia in newly
diabetic NOD mice. Monotherapy with proinsulin/alum
vaccination failed to correct hyperglycemia (Fig. 1D).
In contrast, all mice treated with a combination of
proinsulin/alum and GABA rapidly re-established normo-
glycemia (Fig. 1E). Five of nine mice developed hypergly-
cemia again between 13 and 24 weeks after initiating
treatment. Four mice remained normoglycemic at 20,
30, 45, and 50 weeks post-treatment, suggesting perma-
nent remission in some mice (Fig. 1E). Combined therapy
maintained a significantly longer normoglycemic period
than GABA (20 mg/mL) monotherapy (P = 0.001). These
data demonstrate for the first time that the combination
of ABT with an immunoregulator effectively corrects hy-
perglycemia and can maintain long-term normoglycemia
in newly diabetic NOD mice.
Combined Therapies Induce Antigen-Specific IL-10
Responses in NOD Mice
To understand the mechanisms underlying the therapeutic
effects, female NOD mice at 15 weeks of age were treated
with monotherapy or combined therapy, as described for
newly diabetic mice. Ten days after the second vaccina-
tion, we characterized splenic antigen-specific T cells by
ELISPOT (Fig. 2). There was no significant difference
in the numbers of splenic mononuclear cells among the
different groups of mice (data not shown), and no signif-
icant difference in the frequency of GAD65, HSPp277,
and proinsulin-specific IFN-g–secreting T cells between
alum-vaccinated and unmanipulated control NOD mice
(Fig. 2A). These control mice had few autoantigen-reactive
IL-4 or IL-10 spot-forming cells (Fig. 2B and C), which is
consistent with the notion that unipolar Th1 responses
drive disease progression in NOD mice (24).
Monotherapy with proinsulin or GABA significantly
reduced IFN-g–secreting Th1 responses to all autoanti-
gens tested (Fig. 2A). Proinsulin monotherapy induced
IL-4– and IL-10–secreting T-cell responses to proinsulin
that spread to autoantigens GAD65 and HSPp277, but
not to control self-antigen MSA (Fig. 2B and C). GABA
monotherapy elevated the levels of IL-10, but not IL-4,
responses to proinsulin, GAD65, and HSPp277, but not
to MSA (Fig. 2C). More interestingly, combined therapy
further reduced the frequency of GAD65-, HSPp277-,
and proinsulin-specific Th1 cells (Fig. 2A), and increased
the frequency of IL-10 responses to b-cell autoantigens
to twofold to threefold greater than that of either mono-
therapy (Fig. 2C). Notably, IL-4 responses to b-cell anti-
gens induced by combined therapy were significantly
lower than that of proinsulin monotherapy (Fig. 2B).
Consistent with these findings, monotherapy with pro-
insulin or GABA significantly reduced the levels of
proinsulin-specific IgG2a, and monotherapy with proinsu-
lin, but not with GABA, enhanced IgG1 responses (Fig. 2D).
In contrast, combined therapy significantly decreased
the levels of Ig2a and IgG1 responses relative to proin-
sulin monotherapy. The reduced frequency of auto-
reactive IL-4–secreting T cells and IgG1 responses by
combined therapy suggests that GABA may mitigate
ABT-induced IL-4 responses. Moreover, histological char-
acterization revealed that treatment with GABA or com-
bined therapies (but not with proinsulin monotherapy)
significantly reduced insulitis (insulitis scores 1.008 and
1.006, respectively) compared with those in untreated
mice (1.82, P , 0.01 for both treatments). Collectively,
combined therapy synergistically inhibited pathogenic
T-cell autoimmunity and enhanced IL-10 responses, con-
tributing to the restoration of normoglycemia in newly
diabetic NOD mice.
Combined Treatment With Proinsulin With GABA
Synergistically Increases the Frequency of Splenic
Tregs in NOD Mice
Next, we characterized the frequency of splenic Tregs in
the different groups of NOD mice by flow cytometry. In
comparison with that in unmanipulated NOD mice,
vaccination with alum alone did not significantly alter
the percentages of splenic Tregs (Fig. 2E). In contrast,
vaccination with proinsulin/alum or treatment with
GABA alone increased the frequency of splenic Tregs by
;18% and 50%, respectively. The combination of proin-
sulin and GABA treatments further elevated the percent-
ages of splenic Tregs to ;200% over that in controls, and
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the percentages were significantly higher than that in
mice that received either monotherapy (Fig. 2E). Thus,
consistent with significantly increased IL-10 responses
(Fig. 2C), combined proinsulin and GABA treatments
synergistically enhanced splenic Treg responses in NOD
mice.
Combined Therapy More Effectively Reduces Insulitis
and Increases b-Cell Replication and the Percentage
of Insulin-Producing Cells in the Islets of Newly
Diabetic NOD Mice
Since GABA and proinsulin/alum have immunoregula-
tory actions, and GABA can also promote b-cell survival
and replication, we studied the effect of each therapy on
insulitis and b-cell replication in newly diabetic NOD
mice. Newly diabetic NOD mice were untreated, or
were treated with a monotherapy or combined therapy,
and were provided with water containing BrdU for 10
days. Histological characterization revealed that GABA,
but not proinsulin, monotherapy significantly reduced
the insulitis scores and that combined therapy further
reduced the insulitis scores in newly diabetic NOD mice
(Fig. 3A).
We focused on measuring b-cell replication by Ki67/
insulin immunostaining rather than by determining b-cell
mass because 1) low levels of b-cell replication would be
difficult to detect as a change in b-cell mass and 2) GABA
treatment can promote functional recovery of degranu-
lated b-cells leading to an increase in insulin+ islet cells
and an apparent increase in b-cell mass (19). We observed
almost no insulin+ islet cells in pancreatic islets from un-
treated or proinsulin/alum (only)–treated mice (Fig. 3B
and C), which is consistent with their rapid progression
to severe hyperglycemia during this time period (Fig. 1A
and D). In contrast, Ki67+insulin+ cells were detected in
the islets from the GABA monotherapy and combined
therapy mouse groups, and accounted for ;1.2% and
1.7% of insulin+ cells, respectively (Fig. 3B and C). Simi-
larly, there were ;80 insulin+ cells per islet in the GABA
monotherapy group, and a significantly greater number of
insulin+ cells (120 per islet) in the combined therapy
group, suggesting that combined therapy more effectively
promoted b-cell health and survival. These observations
are consistent with the longitudinal blood glucose levels
(Fig. 1), cellular immune responses (Fig. 2), and insulitis
scores (Fig. 3A).
DISCUSSION
In summary, proinsulin/alum monotherapy had no ability
to correct hyperglycemia. GABAmonotherapy had a limited
Figure 1—Longitudinal blood glucose levels in newly diabetic NOD
given GABA or proinsulin/alum monotherapy or combined treat-
ment. Newly diabetic NOD mice (with two blood glucose levels
>250 mg/dL recorded on consecutive days) were untreated (n =
6) (A) or were continually given GABA, 6 mg/mL (n = 7) (B), or GABA,
20 mg/mL (n = 10) (C), through their drinking water. Other groups of
mice received proinsulin/alum monotherapy (n = 7) (D) or combined
proinsulin/alum + GABA, 20 mg/mL (n = 9) (E). Four of the mice
shown in E remained normoglycemic at 20, 30, 45, and 50 weeks
after initiating treatment (at the time of manuscript proofing). Data
shown are longitudinal blood glucose levels for individual mice.
Note the change of scale in C and E. The dashed line indicates
a blood glucose level of 250 mg/dL. Combined therapy signifi-
cantly prolonged the period of normoglycemia compared with
GABA (20 mg/mL) monotherapy (P = 0.001 by the log-rank test).
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ability to restore normoglycemia in newly diabetic NOD
mice. The combination of these therapies not only rapidly
corrected hyperglycemia, but also restored long-term
normoglycemia in newly diabetic NOD mice. We found
that combined therapies induced antigen-specific IL-10
responses that spread to other b-cell antigens, increased
the frequency of splenic Tregs, and inhibited the severity
of inflammation in the pancreatic islets of NOD mice.
Figure 2—Effect of monotherapy and combined therapy on T-cell immunity and humoral responses. NOD mice at 15 weeks of age were
treated with alum, proinsulin/alum, GABA, or proinsulin/alum + GABA, as described in RESEARCH DESIGN AND METHODS. A control group of mice
received no treatment. Ten days after completing treatment, their splenic T cells were isolated, and the frequency of T cells secreting IFN-g
(A), IL-4 (B), or IL-10 (C ) in response to MSA, proinsulin, GAD65, or HSPp277 was determined by ELISPOT. Responses to control MSA were
at background levels in all mice (data not shown). Data are expressed as the mean number of spot-forming cells (SFCs) 6SEM per million
splenic mononuclear cells. D: The levels of proinsulin-specific IgG, IgG1, and IgG2a antibodies, as determined by ELISA. Data are
expressed as the mean optical density (O.D.) value 6 SEM for each group. E: Effect of monotherapy and combined therapies on Treg
responses, as determined by flow cytometry. Data are expressed as the mean percentage of Tregs 6 SEM. The experimental and control
groups of mice (n = 5 per group) were tested simultaneously in two separate experiments. *P < 0.05, **P < 0.01 vs. the control. #P < 0.05,
##P < 0.01 vs. the proinsulin/alum group. †P < 0.05, ††P < 0.01 vs. the GABA group.
3132 Combined GABA and Proinsulin/Alum Acts Synergistically Diabetes Volume 63, September 2014
GABA monotherapy, and to a greater extent combined
therapy, promoted b-cell replication and preserved
insulin+ cells in newly diabetic NOD mice. Our findings
provide a proof-of-principle that combining ABT with an
immunoregulator can effectively restore normoglycemia
in newly diabetic mice. GABA appears to be safe for hu-
man consumption (20–22) and does not cause general
immunosuppression (10). GABA-Rs are expressed by hu-
man immunocompetent cells and b-cells. Activation of
GABA-Rs can inhibit human T-cell proliferation in vitro
(8,15) and can promote human b-cell replication and sur-
vival in transplanted islets (19). Therefore, the use of
GABA as an immunoregulator in combination with ABTs
or other candidate immunotherapeutics, may hold prom-
ise for T1D intervention in humans.
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